GSK (NYSE: GSK) investors approve all 25 resolutions at 26th AGM

Rhea-AI Filing Summary

GSK plc reported the results of its 26th hybrid Annual General Meeting, where shareholders could participate in person or online. All 25 resolutions were passed on a poll, including the receipt and adoption of the 2025 Annual Report and approval of the annual remuneration report and policy.

Support for the 2025 Annual Report reached 3,073,839,952 votes in favour, or 99.25% of votes cast, with total votes on that resolution representing 76.38% of issued share capital. All directors standing for election or re-election were backed by large majorities, and the auditor’s re-appointment and remuneration were also strongly approved.

Shareholders granted authorities to allot shares, disapply pre-emption rights, and purchase the company’s own shares, with each relevant special resolution receiving well over the required 75% majority. Overall AGM participation, including votes cast and withheld, represented 76.59% of GSK’s issued share capital excluding treasury shares.

Key Figures

Votes for 2025 Annual Report: 3,073,839,952 votes Votes for annual remuneration report: 2,986,046,185 votes Votes for remuneration policy: 3,066,582,993 votes +5 more

8 metrics

Votes for 2025 Annual Report 3,073,839,952 votes Resolution to receive and adopt the 2025 Annual Report; 99.25% of votes cast

Votes for annual remuneration report 2,986,046,185 votes Approval of annual report on remuneration; 96.74% of votes cast

Votes for remuneration policy 3,066,582,993 votes Approval of Remuneration policy; 98.96% of votes cast

Issued share capital 4,054,826,603 shares Ordinary Shares excluding treasury shares as at 1 May 2026

Overall AGM participation 76.59% Total votes cast and withheld as percentage of issued share capital

Authority to purchase own shares 3,093,867,095 votes for Share repurchase authority resolution; 99.82% of votes cast

Votes for general pre-emption disapplication 3,046,584,734 votes Disapplication of pre-emption rights – general power; 98.32% of votes cast

Votes for amended Articles 3,065,959,469 votes Approval of amended Articles of Association; 99.40% of votes cast

Key Terms

hybrid Annual General Meeting, issued share capital, pre-emption rights, Special Resolutions, +2 more

6 terms

hybrid Annual General Meeting financial

"GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm"

issued share capital financial

"The Company's issued share capital as at 1 May 2026 consisted of 4,054,826,603 shares"

Issued share capital is the total value or number of a company's shares that have been created and given to investors, employees or others; think of it as the slices of a cake that have already been cut and distributed. It matters to investors because it determines ownership percentages, potential voting power and how future share sales can dilute existing holdings, affecting share value and control.

pre-emption rights financial

"Disapplication of pre-emption rights - general power"

A shareholder’s right to be offered new shares before they are sold to outsiders, allowing existing owners to buy enough to keep their ownership percentage. Think of it like being offered the first slice of a pie so your share doesn’t shrink; it matters to investors because it protects voting power and economic value from being diluted when a company issues more stock, and it can affect how easy or costly fundraising is.

Special Resolutions financial

"Indicates Special Resolutions requiring a 75% majority of votes cast."

Special resolutions are shareholder votes used to approve major, permanent changes to a company—such as altering the rules, approving mergers, or changing capital structure—and they require a higher-than-normal approval level (commonly a substantial supermajority rather than a simple majority). They matter to investors because they can permanently change rights, ownership or strategy; think of them like needing more than a simple majority to pass a company’s equivalent of a constitutional change.

National Storage Mechanism regulatory

"will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism"

A national storage mechanism is an official, centralized electronic repository where companies and regulators file and keep required corporate documents such as prospectuses, financial statements and regulatory disclosures. For investors it is the authoritative public source to find and verify key papers — like using a government-run public archive or filing cabinet — so you can check the original documents for due diligence, compliance and to confirm claims made in news or marketing.

Form 20-F regulatory

"whether the registrant files or will file annual reports under cover of Form 20-F"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 6 May 2026, London UK

Results of 26th Annual General Meeting

GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 6 May 2026 at the London Marriott Hotel Grosvenor Square, Grosvenor Square, London, W1K 6JP. Shareholders were able to join the meeting in person or virtually via the Lumi Global website and Zoom.

All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

All 25 resolutions were passed and decided upon by a poll. The table below shows the results for each resolution. The full text of the resolutions is contained in the Notice of AGM published on 25 March 2026, which is available on GSK's website at www.gsk.com.

Resolution		Total votes for(1)(2)	%	Total votes against(2)	%	Total votes cast	% of Issued Share Capital voted(3)	Votes withheld(4)
1	Receive and adopt the 2025 Annual Report	3,073,839,952	99.25	23,182,191	0.75	3,097,022,143	76.38%	8,652,004
2	Approve the Annual report on remuneration	2,986,046,185	96.74	100,644,457	3.26	3,086,690,642	76.12%	18,986,231
3	Approve the Remuneration policy	3,066,582,993	98.96	32,182,945	1.04	3,098,765,938	76.42%	6,914,570
4	Election of Luke Miels	3,081,325,569	99.37	19,501,818	0.63	3,100,827,387	76.47%	4,845,132
5	Re-election of Sir Jonathan Symonds	3,079,744,123	99.32	21,127,306	0.68	3,100,871,429	76.47%	4,793,341
6	Re-election of Julie Brown	3,069,722,312	99.00	31,102,814	1.00	3,100,825,126	76.47%	4,848,203
7	Re-election of Elizabeth McKee Anderson	3,042,023,812	98.52	45,732,363	1.48	3,087,756,175	76.15%	17,906,882
8	Re-election of Charles Bancroft	3,070,002,110	99.43	17,646,639	0.57	3,087,648,749	76.15%	18,018,954
9	Re-election of Dr Hal Barron	3,080,985,163	99.37	19,595,495	0.63	3,100,580,658	76.47%	5,088,510
10	Re-election of Dr Anne Beal	3,048,091,490	98.71	39,715,257	1.29	3,087,806,747	76.15%	17,858,160
11	Re-election of Wendy Becker	3,031,625,476	98.18	56,091,438	1.82	3,087,716,914	76.15%	17,946,122
12	Re-election of Dr Harry C Dietz	3,094,560,703	99.80	6,160,152	0.20	3,100,720,855	76.47%	4,943,572
13	Re-election of Dr Jeannie Lee	3,095,593,233	99.84	5,084,831	0.16	3,100,678,064	76.47%	4,985,598
14	Re-election of Dr Gavin Screaton	3,095,403,626	99.83	5,240,337	0.17	3,100,643,963	76.47%	5,019,966
15	Re-election of Dr Vishal Sikka	3,095,036,695	99.82	5,513,088	0.18	3,100,549,783	76.47%	5,111,280
16	Re-appointment of the auditor	3,099,113,772	99.94	1,891,083	0.06	3,101,004,855	76.48%	4,664,323
17	Remuneration of the auditor	3,098,976,181	99.94	1,736,335	0.06	3,100,712,516	76.47%	4,949,197
18	Authority for the company to make donations to political organisations and incur political expenditure	3,039,847,574	98.91	33,534,985	1.09	3,073,382,559	75.80%	32,288,122
19	Authority to allot shares	2,999,108,776	96.74	100,960,760	3.26	3,100,069,536	76.45%	5,592,295
20	Disapplication of pre-emption rights - general power(5)	3,046,584,734	98.32	51,962,919	1.68	3,098,547,653	76.42%	7,072,535
21	Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(5)	3,059,992,748	98.75	38,710,772	1.25	3,098,703,520	76.42%	6,947,940
22	Authority for the company to purchase its own shares(5)	3,093,867,095	99.82	5,669,416	0.18	3,099,536,511	76.44%	6,127,609
23	Exemption from statement of senior statutory auditor's name	3,079,861,236	99.81	5,739,421	0.19	3,085,600,657	76.10%	20,038,163
24	Authority for reduced notice of a general meeting other than an AGM(5)	2,911,856,203	93.98	186,503,587	6.02	3,098,359,790	76.41%	7,285,017
25	Approve the amended Articles of Association(5)	3,065,959,469	99.40	18,375,929	0.60	3,084,335,398	76.07%	21,304,284

Notes:

(1)      The "for" votes include those giving the Chair discretion.

(2)      Votes "for" and "against" are expressed as a percentage of the total votes cast.

(3)      The Company's issued share capital as at 1 May 2026 consisted of 4,054,826,603 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every

           Ordinary Share held.

(4)      A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

(5)      Indicates Special Resolutions requiring a 75% majority of votes cast.

The following table provides further information on participation in the AGM:

	GSK's 26th AGM (Hybrid meeting) (2026)	GSK's 25th AGM (Hybrid meeting) (2025)
Issued share capital (excluding Treasury Shares)	4,054,826,603	4,109,037,095
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)	76.59%	74.21%
Total shareholder population	55,305	57,405
Total number of proxies lodged	2,475	2,617
Number of shareholders in attendance	117 in person 17 participated virtually	130 in person 25 participated virtually
% of shareholders who lodged proxies	4.48%	4.56%

The above poll results will shortly be available on the company's website at www.gsk.com.

In accordance with Listing Rule 6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

V A Whyte

Company Secretary

6 May 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Stree

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: May 06, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) shareholders decide at the 26th Annual General Meeting?

Shareholders approved all 25 resolutions at GSK’s 26th AGM. These included adopting the 2025 Annual Report, approving remuneration reports and policy, re-electing all nominated directors, and granting authorities to issue shares, disapply pre-emption rights, and repurchase the company’s own shares.

How strong was shareholder support for GSK (GSK)’s 2025 Annual Report?

Support for GSK’s 2025 Annual Report was very high, with 3,073,839,952 votes in favour. This represented 99.25% of votes cast on the resolution. Total votes on this item equalled 3,097,022,143, corresponding to 76.38% of GSK’s issued share capital excluding treasury shares.

How did GSK (GSK) shareholders vote on executive remuneration at the AGM?

GSK shareholders approved the annual report on remuneration with 2,986,046,185 votes in favour, or 96.74% of votes cast. The remuneration policy was also endorsed, receiving 3,066,582,993 votes for, equal to 98.96% support, indicating broad backing for the company’s pay framework.

What was overall voting participation at GSK (GSK)’s 2026 AGM?

Total votes cast and withheld at GSK’s 26th AGM represented 76.59% of issued share capital, excluding treasury shares. This compares with 74.21% at the prior year’s AGM, showing a higher level of shareholder engagement in the meeting’s decisions and resolutions.

Did GSK (GSK) receive authority to repurchase its own shares?

Yes. The resolution granting GSK authority to purchase its own shares received 3,093,867,095 votes in favour, or 99.82% of votes cast. Only 5,669,416 votes were against, and the total votes on this resolution represented 76.44% of issued share capital.

How did GSK (GSK) shareholders vote on political donations and expenditure authority?

Shareholders approved the resolution authorising GSK to make donations to political organisations and incur political expenditure. It obtained 3,039,847,574 votes in favour, or 98.91% of votes cast. Votes against totalled 33,534,985, and votes cast on this item represented 75.80% of issued share capital.

What was shareholder turnout and proxy usage at GSK (GSK)’s 2026 AGM?

GSK reported a total shareholder population of 55,305, with 2,475 proxies lodged, meaning 4.48% of shareholders submitted proxies. The meeting was hybrid, with 117 shareholders attending in person and 17 participating virtually via online platforms provided for the AGM.